Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Goldgar

Showing results (41-50 of 75) with videos related to

Pageof 8
Sort By:
JCO Precision Oncology|February 27, 2024
Cancer Risks Associated With <i>TP53</i> Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome SpectrumCristina Fortuno, Bing-Jian Feng, Courtney Carroll, et al.
Journal of the National Cancer Institute|November 30, 2018
Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial RiskMary Beth Terry, Mary B Daly, Kelly Anne Phillips, et al.
Journal of the National Cancer Institute|December 10, 2020
Comparing 5-Year and Lifetime Risks of Breast Cancer using the Prospective Family Study CohortRobert J MacInnis, Julia A Knight, Wendy K Chung, et al.
Cancer Research|February 21, 2006
Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significanceGeorgia Chenevix-Trench, Sue Healey, Sunil Lakhani, et al.
Journal of the National Cancer Institute|March 3, 2020
Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast CancerAnne S Reiner, Mark E Robson, Lene Mellemkjær, et al.
BMJ (Clinical Research Ed.)|September 8, 2012
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)Anouk Pijpe, Nadine Andrieu, Douglas F Easton, et al.
JNCI Cancer Spectrum|December 20, 2019
Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management ToolKelly-Anne Phillips, Yuyan Liao, Roger L Milne, et al.
Plos One|February 15, 2013
Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility allelesFrancisco Javier Gracia-Aznarez, Victoria Fernandez, Guillermo Pita, et al.
American Journal of Human Genetics|April 24, 2012
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasisCatherine T Jordan, Li Cao, Elisha D O Roberson, et al.
Journal of Personalized Medicine|July 2, 2021
Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I)Jennifer D Brooks, Hermann H Nabi, Irene L Andrulis, et al.
Pageof 8

Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
JCO Precision Oncology|February 27, 2024
Cancer Risks Associated With <i>TP53</i> Pathogenic Variants: Maximum Likelihood Analysis of Extended Pedigrees for Diagnosis of First Cancers Beyond the Li-Fraumeni Syndrome SpectrumCristina Fortuno, Bing-Jian Feng, Courtney Carroll, et al.
Journal of the National Cancer Institute|November 30, 2018
Risk-Reducing Oophorectomy and Breast Cancer Risk Across the Spectrum of Familial RiskMary Beth Terry, Mary B Daly, Kelly Anne Phillips, et al.
Journal of the National Cancer Institute|December 10, 2020
Comparing 5-Year and Lifetime Risks of Breast Cancer using the Prospective Family Study CohortRobert J MacInnis, Julia A Knight, Wendy K Chung, et al.
Cancer Research|February 21, 2006
Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significanceGeorgia Chenevix-Trench, Sue Healey, Sunil Lakhani, et al.
Journal of the National Cancer Institute|March 3, 2020
Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast CancerAnne S Reiner, Mark E Robson, Lene Mellemkjær, et al.
BMJ (Clinical Research Ed.)|September 8, 2012
Exposure to diagnostic radiation and risk of breast cancer among carriers of BRCA1/2 mutations: retrospective cohort study (GENE-RAD-RISK)Anouk Pijpe, Nadine Andrieu, Douglas F Easton, et al.
JNCI Cancer Spectrum|December 20, 2019
Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management ToolKelly-Anne Phillips, Yuyan Liao, Roger L Milne, et al.
Plos One|February 15, 2013
Whole exome sequencing suggests much of non-BRCA1/BRCA2 familial breast cancer is due to moderate and low penetrance susceptibility allelesFrancisco Javier Gracia-Aznarez, Victoria Fernandez, Guillermo Pita, et al.
American Journal of Human Genetics|April 24, 2012
Rare and common variants in CARD14, encoding an epidermal regulator of NF-kappaB, in psoriasisCatherine T Jordan, Li Cao, Elisha D O Roberson, et al.
Journal of Personalized Medicine|July 2, 2021
Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I)Jennifer D Brooks, Hermann H Nabi, Irene L Andrulis, et al.
Pageof 8